Apotex Health Corp.
Proudly rooted in Canada, Apotex is a global health company dedicated to advancing health at home and around the world.
Investor website: https://apotex.com/
About
Proudly rooted in Canada, Apotex is a global health company dedicated to advancing health at home and around the world. With five Canadian manufacturing sites, including its global headquarters in Toronto, Apotex manufactures and distributes high-quality medicines, ensuring reliability, safety, and access for Canadians and patients worldwide. As Canada’s largest manufacturer of generic medicines, Apotex is committed to delivering affordable healthcare through a broad portfolio of innovative products, including generics, biosimilars, branded medicines, over-the-counter, and natural health products. The company focuses on filling critical gaps in Canadian care and is guided by integrity and built on trust.
Verified company data
- Shares outstanding
- 228,499,020
- Fully diluted shares
- 247662946
- Projects
- ["Biosimilars: Creating pathways to biosimilars. As a pioneer in oncology biosimilars, we’re transforming access to affordable therapies through innovation, development, and partnerships. With continued investment and an expanding portfolio in new therapeutic areas, we’re breaking barriers to care—delivering high-quality, effective treatments without compromise. - 1&2 top selling biosimilars in Canada - #1 oncology patient support program. [Learn more about our portfolio of biosimilars](https://www.apobiologix.com/en/our_portfolio.asp)","Generics: A force for accessible medicine. As the leader in Canadian generics pharmaceuticals and top 5 in the United States, we bring our experience and track record of making generics affordable and accessible worldwide. Apotex is committed to delivering access with uncompromising quality. With an extensive portfolio of high-quality generic medicines and a robust R&D pipeline, we’re offering accessible treatment worldwide, meeting patients’ needs throughout their lives. Our generic medicines are available in various dosage forms, including oral solid doses and suspensions, capsules, injectables, sprays, powders, inhalers, and drops. - ~460 generic products - ~70 countries where generics are distributed - #1 in prescription volume in Canada - Top ten in the United States - #4 in Mexico's private generics market. Generics play a vital role in empowering patients to achieve better health. They are safe, effective, affordable, and trusted by billions around the world.","Consumer health: Empowering consumers to take charge of their health. Supporting people along their health journeys, our vitamins, supplements and other high-quality natural health products are designed by licensed health practitioners to support optimal health and well-being and delivered to consumers through well-established brands and distribution channels. Learn more about our natural health product brands: - [CanPrev](https://canprev.ca/) - [Orange Naturals](https://orangenaturals.com/) - [CytoMatrix](https://cytomatrix.ca/)"]
- Leadership
- Jeff Watson (President & CEO), Ariel Alon (Chief Operations Officer), Barry Fishman (Chief Corporate Development Officer), Brian McClelland (Chief Financial Officer), Carina Vassilieva (Chief Human Resources Officer), Christine Baeder (President, Apotex USA and LATAM), Francesco Tallarico (Chief Legal Officer and Global Head of Government Relations), Kiran Krishnan (Senior Vice President, Global Regulatory Affairs), Martin Arès (President, Apotex Canada and Rest of World (ROW)), Pradeep Sanghvi (Executive Vice President, Global Research and Development)
Verified data last updated:
Recent filings
- Documents affecting rights of securityholders - Trust indentures re debt · aptx_2026-10-13_11-02-33.pdf
- Documents affecting rights of securityholders - Trust indentures re debt · aptx_2026-10-13_11-02-31.pdf
- Documents affecting rights of securityholders - Trust indentures re debt · aptx_2026-10-13_11-02-30.pdf
- News release · aptx_2026-10-05_16-59-36.pdf
- News release · aptx_2026-10-05_12-17-32.pdf
- News release · aptx_2026-09-28_20-14-42.pdf
- News release · aptx_2026-09-18_12-47-29.pdf
- News release · aptx_2026-09-18_12-46-59.pdf